Certificate of Analysis
Semaglutide
GSA-2026-018432
Purity
99.12%
Lot
SG-2426
Matrix
Peptide
Issued
Apr 6, 2026
Analytical results
| Analyte | Result | Specification | Status |
|---|---|---|---|
| Purity (HPLC) | 99.12 % | ≥ 98 % | PASS |
| Identity (MS/MS) | Confirmed | Match library | PASS |
| Net Peptide Content | 86.4 % | ≥ 80 % | PASS |
| TFA salt | 7.8 % | ≤ 12 % | PASS |
| Endotoxin (LAL) | < 0.5 EU/mg | ≤ 5 EU/mg | PASS |
Client
NovaPeptide Co.
Sample received
Apr 1, 2026
Methods
HPLC + MS/MS
Embed this verification on your site
Paste this where you want the badge. It always reads live from Gold Standard Analytics, so it reflects a retraction immediately and cannot be edited into a false claim.
<iframe src="https://www.goldstandardanalytics.com/embed/coa/GSA-2026-018432" width="100%" height="150" style="border:0;max-width:420px" loading="lazy" title="Gold Standard Analytics COA GSA-2026-018432"></iframe>This certificate was issued by Gold Standard Analytics, an independent third-party laboratory. We test samples submitted to us and report what we measure; we do not manufacture, sell, or endorse any product. Results apply only to the sample as received. Questions? team@goldstandardanalytics.com.